Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil; OK-432 and Montanide; ISA-51 in patients with cancers expressing NY-ESO-1 antigen

Trial Profile

A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil; OK-432 and Montanide; ISA-51 in patients with cancers expressing NY-ESO-1 antigen

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 May 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs NY-ESO-1 ISCOMATRIX (Primary) ; Montanide ISA-51; Picibanil
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Jul 2014 Status changed from recruiting to completed, as per University Hospital Medical Information Network - Japan.
    • 25 Jan 2012 Planned End Date changed from 1 Dec 2010 to 1 Dec 2012 as reported by University Hospital Medical Information Network - Japan.
    • 05 Jun 2009 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top